Development of a neurotoxicity assay that is tuned to detect mitochondrial toxicants

Johannes Delp, Melina Funke, Franziska Rudolf, Andrea Cediel, Susanne Hougaard Bennekou, Wanda van der Stel, Giada Carta, Paul Jennings, Cosimo Toma, Iain Gardner, Bob van de Water, Anna Forsby, Marcel Leist*

*Corresponding author for this work

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Many neurotoxicants affect energy metabolism in man, but currently available test methods may still fail to predict mito- and neurotoxicity. We addressed this issue using LUHMES cells, i.e., human neuronal precursors that easily differentiate into mature neurons. Within the NeuriTox assay, they have been used to screen for neurotoxicants. Our new approach is based on culturing the cells in either glucose or galactose (Glc–Gal–NeuriTox) as the main carbohydrate source during toxicity testing. Using this Glc–Gal–NeuriTox assay, 52 mitochondrial and non-mitochondrial toxicants were tested. The panel of chemicals comprised 11 inhibitors of mitochondrial respiratory chain complex I (cI), 4 inhibitors of cII, 8 of cIII, and 2 of cIV; 8 toxicants were included as they are assumed to be mitochondrial uncouplers. In galactose, cells became more dependent on mitochondrial function, which made them 2–3 orders of magnitude more sensitive to various mitotoxicants. Moreover, galactose enhanced the specific neurotoxicity (destruction of neurites) compared to a general cytotoxicity (plasma membrane lysis) of the toxicants. The Glc–Gal–NeuriTox assay worked particularly well for inhibitors of cI and cIII, while the toxicity of uncouplers and non-mitochondrial toxicants did not differ significantly upon glucose ↔ galactose exchange. As a secondary assay, we developed a method to quantify the inhibition of all mitochondrial respiratory chain functions/complexes in LUHMES cells. The combination of the Glc–Gal–NeuriTox neurotoxicity screening assay with the mechanistic follow up of target site identification allowed both, a more sensitive detection of neurotoxicants and a sharper definition of the mode of action of mitochondrial toxicants.

Original languageEnglish
Pages (from-to)1585-1608
Number of pages23
JournalArchives of Toxicology
Volume93
Issue number6
Early online date1 Jun 2019
DOIs
Publication statusPublished - 12 Jun 2019

Funding

This work was supported by the Land-BW (INVITE, NEURODEG), the BMBF (e:ToP program, NeuriTox), UKN/DFG (KoRS-CB) and the Projects from the European Union's Horizon 2020 research and innovation programme EU-ToxRisk (grant agreement No 681002) and ENDpoiNTs (grant agreement No 825759). We thank Dr. Philipp Secker for fruitful discussions about the mitochondrial complex activity assay. This work was supported by the Land-BW (INVITE, NEURODEG), the BMBF (e:ToP program, NeuriTox), UKN/DFG (KoRS-CB) and the Projects from the European Union's Horizon 2020 research and innovation programme EU-ToxRisk (grant agreement No 681002) and ENDpoiNTs (grant agreement No 825759). We thank Dr. Philipp Secker for fruitful discussions about the mitochondrial complex activity assay.

FundersFunder number
European Union's Horizon 2020 research and innovation programme EU-ToxRisk825759
UKN
UKN/DFG
Horizon 2020 Framework Programme681002
Deutsche Forschungsgemeinschaft
Bundesministerium für Bildung und Forschung

    Keywords

    • High content imaging
    • High-throughput toxicity screening
    • Mechanistic safety assessment
    • Metabolic reprogramming
    • Mitotoxicity
    • Neurotoxicity

    Fingerprint

    Dive into the research topics of 'Development of a neurotoxicity assay that is tuned to detect mitochondrial toxicants'. Together they form a unique fingerprint.

    Cite this